Imigrane (Sumatriptan Succinate)

Sumatriptan selectively stimulates serotonin 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve endings. This action causes vasoconstriction of dilated intracranial vessels and blocks the release of inflammatory neuropeptides, thereby interrupting the migraine pain cascade.

The dose of Imigrane is determined by the prescribing clinician based on the individual patient's needs, severity of migraine, and response to therapy. The prescriber will select the appropriate tablet strength and timing according to approved labeling and clinical guidelines.

Safety data for sumatriptan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative options with their healthcare provider.

To order Imigrane, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details, and any necessary import documentation.

Imigrane (sumatriptan) belongs to the triptan class, which is specifically designed for acute migraine relief. Compared with non‑specific analgesics, triptans target serotonin receptors to address the underlying vascular and neurogenic mechanisms of migraine, often providing faster and more complete headache resolution. Other triptans have similar efficacy but may differ in onset time and side‑effect profile.

Imigrane tablets should be stored at temperatures below 25 °C, in their original container, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Imigrane is taken orally as a tablet, preferably with a glass of water, at the first sign of a migraine attack. The tablet should be swallowed whole and not crushed or chewed. Patients should follow the dosing instructions provided by their prescriber and avoid taking another dose within 24 hours unless directed.

Serious risks include coronary vasospasm, myocardial ischemia, severe hypertension, and serotonin syndrome, especially when combined with other serotonergic drugs. Patients experiencing chest pain, severe headache, visual disturbances, or signs of an allergic reaction should seek immediate medical attention.

Imigrane is contraindicated in patients with a history of ischemic heart disease, uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to sumatriptan or any tablet excipients. It should also be avoided in individuals who have taken other triptans, ergotamine derivatives, or MAO inhibitors within the past 24 hours.